Gene
GNAQ
GNAQ is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (12), Actionable biomarkers (4), Trial mentions (55), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention GNAQ. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 6 of 8,738 | 0.07% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 6 of 8,275 | 0.07% | 10 of 11,460 | 0.09% |
| 2022 | 5 of 8,285 | 0.06% | 8 of 13,598 | 0.06% |
| 2021 | 2 of 8,692 | 0.02% | 9 of 15,045 | 0.06% |
| 2020 | 2 of 7,640 | 0.03% | 10 of 14,459 | 0.07% |
| 2019 | 3 of 7,300 | 0.04% | 19 of 12,159 | 0.16% |
| 2018 | 4 of 6,927 | 0.06% | 7 of 11,854 | 0.06% |
| 2017 | 2 of 6,558 | 0.03% | 13 of 11,595 | 0.11% |
Showing 10 of 37 years.
Assay-provider ledger (12)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Peter MacCallum Cancer Centre | Not a company | Clinical validation | 1 | July 01, 2025 |
| Memorial Sloan Kettering Cancer Center | Not a company | No clinical or analytical validation recorded for this pair | 1 | December 01, 2020 |
| UPMC Molecular & Genomic Pathology (MGP) Laboratory | Not a company | Clinical validationAnalytical validation | 1 | January 01, 2020 |
| Affymetrix | Reagent supplier | Clinical validationAnalytical validation | 2 | July 01, 2018 |
| Agilent Technologies | Reagent supplier | Analytical validation | 1 | January 24, 2017 |
Showing 5 of 12 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| GNAQ (Q209) | Pkc Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| GNAQ (Q209) | Pi3k Pathway Inhibitor + Mek Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| GNAQ (Q209) | Selumetinib | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| GNAQ (Q209) | Hdac Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
Trial mentions (55)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05179174 | Trial biospecimen (AACT) |
| NCT07866651 | Trial eligibility (AACT) |
| NCT04116372 | Trial eligibility (AACT) |
| NCT06060613 | Trial eligibility (AACT) |
| NCT07441343 | Trial eligibility (AACT) |
Showing 5 of 55 trial mentions.
Target-disease associations (401)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal cardiovascular system morphology | phenotype | eva somatic |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Albinism-deafness syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alkalosis | phenotype | GWAS credible sets |
| Alopecia universalis | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 401 associations.
Vendor sourcing (145)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.862C>A (p.L288I) alteration is located in exon 6 (coding exon 6) of the GNAQ gene. This alteration results from a C to A substitution at nucleotide pos... | View ClinVar record SCV003621576.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histopathologically confirmed diagnosis of metastatic or unresectable uveal melanoma. Note - Documentation of mutation status for uveal melanoma will no... | View trial NCT02768766 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | GNAQ | View trial NCT02768766 |
| Bayer (Germany) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients older than 18 years old and younger than 70 years. * To have diagnosis of erectile dysfunction by IIEF. Qualification less than 46 points and/o... | View trial NCT00555087 |
| Bayer (Germany) | Trial collaborator | Mentioned in trial textTrial free-text mention | GAQ | View trial NCT00555087 |
Showing 5 of 145 sourcing records.
Trial-cited literature (132)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. | Clinical pharmacology and therapeutics | 2026 | 2 |
| Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM). | iScience | 2025 | 1 |
| A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | 15 |
| Intratumoral administration of the immunologic adjuvant AS01<sub>B</sub> in combination with autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. | Journal for immunotherapy of cancer | 2024 | 8 |
| YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. | Nature cancer | 2023 | 286 |
Showing 5 of 132 papers.
Literature-extracted relations (20)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| MERCAPTOPURINE | Chemical | associate |
Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. | 2026 |
| Lidocaine | Chemical | associate |
Time-dependent inhibition of G protein-coupled receptor signaling by local anesthetics. | 2004 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. | 2026 |
| Pre-Eclampsia | Disease | stimulate |
Mitochondrial-targeted antioxidant attenuates preeclampsia-like phenotypes induced by syncytiotrophoblast-specific Gαq signaling. | 2023 |
| Glioblastoma | Disease | associate |
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. | 2023 |
Showing 5 of 20 relation assertions.
Organizations publishing (190)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 10 | 1992 to 2023 |
| The University of Texas System | Academic | 9 | 2010 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 8 | 2011 to 2022 |
| Vanderbilt Health | Industry | 7 | 2012 to 2023 |
| Mass General Brigham | Hospital | 6 | 2011 to 2023 |
Showing 5 of 190 organizations.
Where GNAQ appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- urinary system disease
369 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.